Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy.

Ling X, Zhang S, Liu Y, Bai M
J Biomed Opt. 2018 23 (10): 1-9

PMID: 30334393 · DOI:10.1117/1.JBO.23.10.108001

Cannabinoids are emerging as promising antitumor drugs. However, complete tumor eradication solely by cannabinoid therapy remains challenging. In this study, we developed a far-red light activatable cannabinoid prodrug, which allows for tumor-specific and combinatory cannabinoid and photodynamic therapy. This prodrug consists of a phthalocyanine photosensitizer (PS), reactive oxygen species (ROS)-sensitive linker, and cannabinoid. It targets the type-2 cannabinoid receptor (CB2R) overexpressed in various types of cancers. Upon the 690-nm light irradiation, the PS produces cytotoxic ROS, which simultaneously cleaves the ROS-sensitive linker and subsequently releases the cannabinoid drug. We found that this unique multifunctional prodrug design offered dramatically improved therapeutic efficacy, and therefore provided a new strategy for targeted, controlled, and effective antitumor cannabinoid therapy.

(2018) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE).

MeSH Terms (14)

Animals Antineoplastic Agents Cannabinoids Cell Line, Tumor Cell Survival HEK293 Cells Humans Indoles Mice Organosilicon Compounds Photochemotherapy Photosensitizing Agents Prodrugs Reactive Oxygen Species

Connections (1)

This publication is referenced by other Labnodes entities: